1 |
Klippel JH. Rheumatology. 3rd ed. London: Mosby Co, 2004:1292
|
2 |
Wananukul S, Watana D, Pongprasit P. Cutaneous manifestations of childhood systemic lupus erythematosus. Pediatr Dermatol 1998;15:342-6
DOI
ScienceOn
|
3 |
Smith FE, Sweet DE, Brunner CM, Davis JS. Avascular necrosis in SLE: an apparent predilection for young patients. Ann Rheum Dis 1976;35:227-32
DOI
ScienceOn
|
4 |
Silber TJ, Chatoor I, White PH. Psychiatric manifestations of systemic lupus erythematosus in children and adolescents. Clin Pediatr 1984;23:331-5
DOI
ScienceOn
|
5 |
Ansari A, Larson PH, Bates HD. Vascular manifestations of systemic lupus erythematosus. Angiology 1986;37:423-32
DOI
ScienceOn
|
6 |
Sharp GC, Irvin WS, Tan EM. Mixed connective tissue disease: an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen. Am J Med 1972;52:148-59
DOI
ScienceOn
|
7 |
Egner W. The use of laboratory tests in the diagnosis of SLE. J Clin Pathol 2000;53:424-32
DOI
|
8 |
Mandell BF, Raps ED. Severe systemic hypersensitivity reaction of ibuprofen occurring after prolonged therapy. Am J Med 1987;82:817-20
DOI
ScienceOn
|
9 |
Chatham WW, Kimberly RP. Treatment of lupus with corticosteroids. Lupus 2002;10:140-7
DOI
|
10 |
Athreya BH, Rafferty JH, Sehgal GS, Lahita RG. Adenohypophyseal and sex hormones in pediatric rheumatic diseases. J Rheumatol 1993;20:725-30
|
11 |
Manderson AP, Botto M, Walport MJ. The role of complement in the development of systemic lupus erythematosus. Annu Rev Immunol 2004;22:431-56
DOI
ScienceOn
|
12 |
Lehman TJ, Edelheit BS, Onel KB. Combined intravenous methotrexate and cyclophosphamide for refractory childhood lupus nephritis. Ann Rheum Dis 2004;63:321-23
DOI
ScienceOn
|
13 |
Wallace DJ, Metzger AL, Stecher VJ. Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids. Am J Med 1990;89:322-6
DOI
ScienceOn
|
14 |
Ilowite NT, Samuel P, Ginzler E. Dyslipoproteinemia in pediatric systemic lupus erythematosus. Arthritis Rheum 1988;31:859-63
DOI
ScienceOn
|
15 |
Fritzler MJ, Tan EM. Antibodies to histone in druginduced and idiopathic lupus erythematosus. J Clin Invest 1978;62:560-7
DOI
|
16 |
Fu LW, Yang LY, Chen WP, Lin CY. Clinical efficacy of cyclosporin A(Neoral) in the treatment of paediatric lupus nephritis with heavy protenuria. Br J Rheumatol 1998;37: 217-21
DOI
|
17 |
Cameron JS. Lupus nephritis in childhood and adolescene. Pediatr Nephrol 1994;8:230-49
DOI
|
18 |
Beaufils M, Kouki F, Mignon F. Clinical significance of anti-Sm antibodies in systemic lupus erythematosus. Am J Med 1983;74:201-5
DOI
ScienceOn
|
19 |
Osler W. On the visceral complications of erythema exudativum multiforme. Am J Med 1895;110:629-46
DOI
|
20 |
Clinic Rheumatology editors. Clinic Rheumatology IN: Systemic lupus erythematosus. 1st ed. Seoul: Korea Medicine Co, 2006:353-406
|
21 |
Bowyer SL, Ragsdale CG, Sullivan DB. Factor VIII related antigen and childhood rheumatic diseases. J Rheumatol 1989;16:1093-97.
|
22 |
Abu-Shakra M, Shoenfeld Y. Azathioprine therapy for patients with systemic lupus erythematsus. Lupus 2001;10: 152-3
DOI
ScienceOn
|
23 |
Valesini G, Priori R, Francia A. Central nervous system involvement in systemic lupus erythematosus: a new therapeutic approach with intrathecal dexamethasone and methotrexate. Springer Semi Immunopatho 1994;16:313-21
|
24 |
Libman E, Sacks B. A hitherto undescribed form of valvular and mural endocarditis. Arch Intern Med 1924;33:701- 37
DOI
|
25 |
Malleson PN, Fung MY, Rosenberg AM. The incidence of pediatric rheumatic diseases: result from the Canadian Pediatric Rheumatology Association Disease Registry. J Rheumatol 1996;23:1981-7
|
26 |
Kokk A, Horneff G, Wilgenbus KK. Acute lethal necrotising pancreatitis in childhood systemic lupus erythematosus. Possible toxicity of immunosuppressive therapy. Clin Exp Rheumatol 1995;13:399-403
|
27 |
Baehr G, Kemperer P, Schifrin A. A diffuse disease of the peripheral circulation usually associated with lupus erythematsus and endocraditis. Trans Assoc Am Phys 1935; 50:139
|
28 |
Felson DT, Anderson J. Evidence for the superiority of immunosuppressive drugs and prednisone over prednisone alone in lupus nephritis: results of a pooled analysis. N Engl J Med 1984;311:1528-33
DOI
ScienceOn
|
29 |
Miranda-Carus ME, Anhalt G, Rosen A. Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J Exp Med 1994;179:1317-30
DOI
|
30 |
Ginzler EM, Aranow C, Buyon J. A multicenter study of mycophenolate mofetil(MMF) vs intravenous cyclophosphamide( IVC) as induction therapy for severe lupus nephritis: preliminary results. Arthritis Rheum 2003;48:s647
|
31 |
Reichlin M. Antibodies to ribonuclear proteins in systemic lupus erythematosus. Rheum Dis Clin North Am 1994;20: 29-43
|
32 |
Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725
|
33 |
Taylor PV, Scott JS, Gerlis LM. Maternal autoantibodies against fetal cardiac antigens in congenital complete heart block. N Engl J Med 1986;315:667-72
DOI
ScienceOn
|
34 |
Gibson T, Myers AR. Subclinical liver disease in systemic lupus erythemato년. J Rheumatol 1981;8:752-9
|
35 |
Smith CD, Cyr M. The history of lupus erythematosus from Hippocrates to Osler. Rheum Dis Clin North Am 1988;14:1-14
|
36 |
Au A, O'Day J. Review of severe vaso-occlusive retinopathy in systemic lupus erythematosus and the antiphospholipid syndrome: association, visual outcomes, complications and treatment. Clin Exp Opthalmol 2004;32:87-100
DOI
ScienceOn
|
37 |
Hargraves MM, Richmond H, Morton R. Presentation of two bone marrow elements: the Tart cell and the L.E. cell. Mayo Clin Proc 1948;23:25-8
|
38 |
Abu-Shakra M, Gladman DD, Urowitz MB. Malignancy in systemic lupus erythematosus. Arthritis Rheum 1996;39: 1050-5
DOI
ScienceOn
|
39 |
Takada K, Illei GG, Boumpas DT. Cyclophosphamide for the treatments of systemic lupus erythematosus. Lupus 2001;10:154-61
DOI
|
40 |
Lafferty TE, Smith JB, Schuster SJ, DeHortius RJ. Treatment of acquired factor VIII inhibitor using intravenous immunoglobulin in two patients with systemic lupus erythematosus. Rrthritis Rheum 1997;40:775-8
DOI
|
41 |
Lehman TJ, Hanson V, Singsen BH. The role of antibodies directed against double-stranded DNA in the manifestations of systemic lupus erythematosus in childhood. J Pediatr 1980;96:657-61
DOI
|
42 |
Wang LC, Yang YH, Lu MY. Retrospective analysis of mortality and morbidity of pediatric SLE in the past two decades. J Mirobiol Immunol Infect 2003;36:203-8
|
43 |
Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7
DOI
ScienceOn
|
44 |
Johnson AE, Gordon C, Palmer RG, Bacon PA. The prevalence and incidence of systemic lupus erythematosus in Birmingham, England: relationship to ethnicity and country of birth. Arthritis Rheum 1995;38:551-8
DOI
ScienceOn
|
45 |
Cassidy JT, Petty RE, Laxer RM, Lindsley CB. Textbook of Pediatrics Rheumatology. IN: Petty RE. Laxer RM, editors. Systemic Lupus Erythematosus. 5th ed. Philadelphia: Elsevier Saunders Ins, 2005:342-91
|
46 |
Incaprera M, Rindi L, Bazzichi A, Garzelli C. Potential role of the Epstein-Barr virus in systemic lupus erythematosus autoimmunity. Clin Exp Rheumatol 1998;16:289-94
|
47 |
De Jongste JC, Neijens HJ, Duiverman EJ. Respiratory tract disease in systemic lupus erythematosus. Arch Dis Child 1986;61:478-83
DOI
|